U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C33H43FO7
Molecular Weight 570.6887
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXAMETHASONE CIPECILATE

SMILES

[H][C@@]12C[C@@H](C)[C@](OC(=O)C3CC3)(C(=O)COC(=O)C4CCCCC4)[C@@]1(C)C[C@H](O)[C@@]5(F)[C@@]2([H])CCC6=CC(=O)C=C[C@]56C

InChI

InChIKey=JPTKVJWWVFLEJL-GVPGRCOTSA-N
InChI=1S/C33H43FO7/c1-19-15-25-24-12-11-22-16-23(35)13-14-30(22,2)32(24,34)26(36)17-31(25,3)33(19,41-29(39)21-9-10-21)27(37)18-40-28(38)20-7-5-4-6-8-20/h13-14,16,19-21,24-26,36H,4-12,15,17-18H2,1-3H3/t19-,24+,25+,26+,30+,31+,32+,33+/m1/s1

HIDE SMILES / InChI

Molecular Formula C33H43FO7
Molecular Weight 570.6887
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/67018038

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune response. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
MAXIDEX

Approved Use

Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.

Launch Date

-2.37859193E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.37859193E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
Neofordex

Approved Use

Neofordex is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products.

Launch Date

1.45799997E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
9.87 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
51.2 ng × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.93 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
30%
DEXAMETHASONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
96 mg multiple, oral (total)
Dose: 96 mg
Route: oral
Route: multiple
Dose: 96 mg
Sources:
unhealthy, 63 years (range: 30–78 years)
n = 21
Health Status: unhealthy
Age Group: 63 years (range: 30–78 years)
Sex: M+F
Population Size: 21
Sources:
0.1 % 3 times / day multiple, ophthalmic
Dose: 0.1 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 0.1 %, 3 times / day
Sources:
unhealthy, 68.3 years (range: 51.0 - 83.0 years)
n = 77
Health Status: unhealthy
Age Group: 68.3 years (range: 51.0 - 83.0 years)
Sex: M+F
Population Size: 77
Sources:
Other AEs: Corneal erosion...
Other AEs:
Corneal erosion (10%)
Sources:
0.6 mg/kg single, oral
Dose: 0.6 mg/kg
Route: oral
Route: single
Dose: 0.6 mg/kg
Sources:
unhealthy, children
n = 6
Health Status: unhealthy
Condition: Migraine
Age Group: children
Population Size: 6
Sources:
Other AEs: Constipation...
Other AEs:
Constipation (below serious, 1 patient)
Sources:
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
n = 106
Health Status: unhealthy
Condition: Migraine
Population Size: 106
Sources:
Other AEs: Drowsiness, Dizziness...
Other AEs:
Drowsiness (below serious, 19 patients)
Dizziness (below serious, 3 patients)
Adverse drug reaction NOS (below serious, 10 patients)
Sources:
12 mg 1 times / day multiple, intravenous
Dose: 12 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Knee Arthroplasty
Population Size: 10
Sources:
Other AEs: Wound dehiscence...
Other AEs:
Wound dehiscence (below serious, 1 patient)
Sources:
20 mg single, intravenous
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
unhealthy
Health Status: unhealthy
Sources:
24 mg 1 times / day multiple, intravenous
Dose: 24 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Knee Arthroplasty
Population Size: 10
Sources:
Other AEs: Dizziness...
Other AEs:
Dizziness (below serious, 1 patient)
Sources:
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Other AEs: Constipation, Dyspepsia...
Other AEs:
Constipation (below serious, 47 patients)
Dyspepsia (below serious, 12 patients)
Vomiting (below serious, 9 patients)
Fatigue (below serious, 58 patients)
Cholesterol high (below serious, 8 patients)
Anorexia (below serious, 15 patients)
Anxiety (below serious, 11 patient)
Insomnia (below serious, 26 patients)
Cough (below serious, 9 patients)
Dyspnea (below serious, 20 patients)
Sources:
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Other AEs: Incision site bleeding, Body temperature decrease...
Other AEs:
Incision site bleeding (below serious, 1 patient)
Body temperature decrease (below serious, 2 patients)
Shivering (below serious, 1 patient)
Tachycardia (below serious, 1 patient)
Transfusion (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Corneal erosion 10%
0.1 % 3 times / day multiple, ophthalmic
Dose: 0.1 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 0.1 %, 3 times / day
Sources:
unhealthy, 68.3 years (range: 51.0 - 83.0 years)
n = 77
Health Status: unhealthy
Age Group: 68.3 years (range: 51.0 - 83.0 years)
Sex: M+F
Population Size: 77
Sources:
Constipation below serious, 1 patient
0.6 mg/kg single, oral
Dose: 0.6 mg/kg
Route: oral
Route: single
Dose: 0.6 mg/kg
Sources:
unhealthy, children
n = 6
Health Status: unhealthy
Condition: Migraine
Age Group: children
Population Size: 6
Sources:
Adverse drug reaction NOS below serious, 10 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
n = 106
Health Status: unhealthy
Condition: Migraine
Population Size: 106
Sources:
Drowsiness below serious, 19 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
n = 106
Health Status: unhealthy
Condition: Migraine
Population Size: 106
Sources:
Dizziness below serious, 3 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
n = 106
Health Status: unhealthy
Condition: Migraine
Population Size: 106
Sources:
Wound dehiscence below serious, 1 patient
12 mg 1 times / day multiple, intravenous
Dose: 12 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Knee Arthroplasty
Population Size: 10
Sources:
Dizziness below serious, 1 patient
24 mg 1 times / day multiple, intravenous
Dose: 24 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Knee Arthroplasty
Population Size: 10
Sources:
Anxiety below serious, 11 patient
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Dyspepsia below serious, 12 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Anorexia below serious, 15 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Dyspnea below serious, 20 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Insomnia below serious, 26 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Constipation below serious, 47 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Fatigue below serious, 58 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Cholesterol high below serious, 8 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Cough below serious, 9 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Vomiting below serious, 9 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Incision site bleeding below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Shivering below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Tachycardia below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Transfusion below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Body temperature decrease below serious, 2 patients
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: These data demonstrate that dexamethasone at doses used clinically increased CYP3A4 activity with extensive intersubject variability and that the extent of CYP3A4 induction was, in part, predicted by the baseline activity of CYP3A4 in both healthy volunteers and human hepatocyte cultures.
Page: -
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Regulation of RANTES and ICAM-1 expression in murine mesangial cells.
1997 Apr
The role of pulmonary inflammation in the development of pulmonary hypertension in newborn with meconium aspiration syndrome (MAS).
1999
Functional assay of NF-kappaB translocation into nuclei by laser scanning cytometry: inhibitory effect by dexamethasone or theophylline.
1999 Apr
Glucocorticoids inhibit proliferation and adhesion of the IL-3-dependent mast cell line, MC/9, to NIH/3T3 fibroblasts, with an accompanying decrease in IL-3 receptor expression.
1999 Apr
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
1999 Aug 12
Inhibition of heat shock factor activity prevents heat shock potentiation of glucocorticoid receptor-mediated gene expression.
1999 Dec
Inhibition of transforming growth factor beta1-induced hepatoma cell apoptosis by liver tumor promoters: characterization of primary signaling events and effects on CPP32-like caspase activity.
1999 Feb
Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation.
1999 Feb
Dexamethasone induces apoptosis in human T cell clones expressing low levels of Bcl-2.
1999 Jan
Structure, evolution, and liver-specific expression of sterol 12alpha-hydroxylase P450 (CYP8B).
1999 Jul
Differential regulation of peptide alpha-amidation by dexamethasone and disulfiram.
1999 Jun
Induction of stromelysin gene expression by tumor necrosis factor alpha is inhibited by dexamethasone, salicylate, and N-acetylcysteine in synovial fibroblasts.
1999 Jun
The anti-emetic efficacy of tropisetron plus dexamethasone in patients treated with high-dose chemotherapy and stem cell transplantation.
1999 Mar
Pharmacological validation of a feline model of steroid-induced ocular hypertension.
1999 Mar
Intestinal damage induced by zinc deficiency is associated with enhanced CuZn superoxide dismutase activity in rats: effect of dexamethasone or thyroxine treatment.
1999 May
Effect of arsenite on induction of CYP1A, CYP2B, and CYP3A in primary cultures of rat hepatocytes.
1999 May 15
Effects of theophylline, dexamethasone and salbutamol on cytokine gene expression in human peripheral blood CD4+ T-cells.
1999 Nov
Early (4-7 days of age) dexamethasone therapy for prevention of chronic lung disease in preterm infants.
1999 Nov
Pharmacological and histopathological study of cyclophosphamide-induced hemorrhagic cystitis - comparison of the effects of dexamethasone and Mesna.
1999 Oct
Blockade of cocaine-induced increases in adrenocorticotrophic hormone and cortisol does not attenuate the subjective effects of smoked cocaine in humans.
1999 Sep
Dexamethasone increases eNOS gene expression and prevents renal vasoconstriction induced by cyclosporin.
1999 Sep
Melatonin regulates glucocorticoid receptor: an answer to its antiapoptotic action in thymus.
1999 Sep
Morphine induced allodynia in a child with brain tumour.
1999 Sep 4
Antenatal dexamethasone improves atrial natriuretic peptide receptors in hypoplastic lung in nitrofen-induced diaphragmatic hernia in rats.
2000
Immune abnormalities in aneurysmal subarachnoid haemorrhage patients: relation to delayed cerebral vasospasm.
2000 Apr
Dexamethasone suppresses tumor necrosis factor-alpha-induced apoptosis in osteoblasts: possible role for ceramide.
2000 Aug
Effects of dexamethasone on mitogen-activated protein kinases in mouse macrophages: implications for the regulation of 85 kDa cytosolic phospholipase A(2).
2000 Aug 15
Suppressive effect of active hexose correlated compound (AHCC) on thymic apoptosis induced by dexamethasone in the rat.
2000 Dec
Low doses of oral dexamethasone for hormone-refractory prostate carcinoma.
2000 Dec 15
Prenatal exposure to high levels of glucocorticoids increases the susceptibility of cerebellar granule cells to oxidative stress-induced cell death.
2000 Dec 19
Effect of polyunsaturated fatty acids on dexamethasone-induced gastric mucosal damage.
2000 Feb
Antenatal dexamethasone enhances endothelin receptorB expression in hypoplastic lung in nitrofen-induced diaphragmatic hernia in rats.
2000 Feb
Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats.
2000 Feb
Dexamethasone blocks sepsis-induced protection of the heart from ischemia reperfusion injury.
2000 Jan
Inhibition of carrageenan-induced edema by indomethacin or sodium salicylate does not prevent the increase of nerve growth factor in the rat hind paw.
2000 Jan 14
Combined administration of G-CSF and dexamethasone for the mobilization of granulocytes in normal donors: optimization of dosing.
2000 Jun
Down-regulation of thyroid transcription factor-1 gene expression in fetal lung hypoplasia is restored by glucocorticoids.
2000 Jun
Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding.
2000 Jun 23
Regulation of vitamin D-1alpha-hydroxylase and -24-hydroxylase expression by dexamethasone in mouse kidney.
2000 Mar
Effects of selected herbicides on cytokine production in vitro.
2000 May 19
Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone.
2000 May-Jun
Regulation of leptin release by troglitazone in human adipose tissue.
2000 Nov
Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats.
2000 Nov
Dexamethasone-induced cardiogenic shock rescued by percutaneous cardiopulmonary support (PCPS) in a patient with pheochromocytoma.
2000 Oct
Role of caspases in dexamethasone-induced apoptosis and activation of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase in human eosinophils.
2000 Oct
Endotoxin augments cerebral hyperemic response to halothane by inducing nitric oxide synthase and cyclooxygenase.
2000 Oct
Endocrinologic and psychological effects of short-term dexamethasone in anorexia nervosa.
2000 Sep
The clinical impact of metabolic bone disease in coeliac disease.
2001 Jan
Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen.
2001 Jan
Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network.
2001 Jan 11
Patents

Sample Use Guides

One or two drops topically in the conjunctival sac(s). In severe disease, drops may be used hourly. In mild disease, drops may be used up to four to six times daily.
Route of Administration: Other
Caco-2 cells were treated with 1 μM dexamethasone and SGK1 mRNA levels were determined by Northern blot analysis. Figure 1A shows that dexamethasone rapidly induced SGK1 mRNA expression as early as 30 min and maintained the elevated expression for at least 24 h.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:06:53 UTC 2023
Edited
by admin
on Fri Dec 15 16:06:53 UTC 2023
Record UNII
T51D685OXG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEXAMETHASONE CIPECILATE
INN   JAN   WHO-DD  
INN  
Official Name English
DEXAMETHASONE CIPECILATE [JAN]
Common Name English
Dexamethasone Cipecilate [WHO-DD]
Common Name English
dexamethasone cipecilate [INN]
Common Name English
9-FLUORO-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3,20-DIOXOPREGNA-1,4-DIENE-17,21-DIYL 21-CYCLOHEXANECARBOXYLATE 17-CYCLOPROPANECARBOXYLATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C521
Created by admin on Fri Dec 15 16:06:54 UTC 2023 , Edited by admin on Fri Dec 15 16:06:54 UTC 2023
Code System Code Type Description
CAS
132245-57-9
Created by admin on Fri Dec 15 16:06:54 UTC 2023 , Edited by admin on Fri Dec 15 16:06:54 UTC 2023
PRIMARY
FDA UNII
T51D685OXG
Created by admin on Fri Dec 15 16:06:54 UTC 2023 , Edited by admin on Fri Dec 15 16:06:54 UTC 2023
PRIMARY
EVMPD
SUB35396
Created by admin on Fri Dec 15 16:06:54 UTC 2023 , Edited by admin on Fri Dec 15 16:06:54 UTC 2023
PRIMARY
NCI_THESAURUS
C77416
Created by admin on Fri Dec 15 16:06:54 UTC 2023 , Edited by admin on Fri Dec 15 16:06:54 UTC 2023
PRIMARY
SMS_ID
100000128389
Created by admin on Fri Dec 15 16:06:54 UTC 2023 , Edited by admin on Fri Dec 15 16:06:54 UTC 2023
PRIMARY
INN
8632
Created by admin on Fri Dec 15 16:06:54 UTC 2023 , Edited by admin on Fri Dec 15 16:06:54 UTC 2023
PRIMARY
EPA CompTox
DTXSID50927596
Created by admin on Fri Dec 15 16:06:54 UTC 2023 , Edited by admin on Fri Dec 15 16:06:54 UTC 2023
PRIMARY
PUBCHEM
15159004
Created by admin on Fri Dec 15 16:06:54 UTC 2023 , Edited by admin on Fri Dec 15 16:06:54 UTC 2023
PRIMARY
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
ACTIVE MOIETY